SVRASavara Inc
$5.24
$0.05
(0.96%)
Closed $5.15
$0.09
(1.75%)
After Hours
Reported EarningsMay 12
Mkt Cap$1.07B
Vol2.07M
Fundamentals
Mkt Cap
$1.07B
Volume
-
52W High
$7.01
52W Low
$1.98
PE Ratio
-9.22
Avg. Volume
1.28M
EPS (Annual)
-$0.5344
Rev/Employee
$0.00
Earnings
May 12
Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team will host one-on-one meetings and participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on...
Business Wire
Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the ATS 2026 International Conference that is taking place May 15-20, 2026, in Orlando, Florida. The poster reported new biomarker data from the...
Business Wire
Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the ATS 2026 International Conference that is taking place May 15-20, 2026, in Orlando, Florida. The poster reports long-term efficacy and safety data...
Business Wire
Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, sponsored an oral presentation at the ATS 2026 International Conference that is taking place May 15-20, 2026, in Orlando, Florida. The presentation reported new exercise...
Business Wire
Savara Reports First Quarter Financial Results and Provides Business Update
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the first quarter ending March 31, 2026 and...
Business Wire
Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team will participate in a...
Business Wire
Savara (SVRA) to Release Earnings on Tuesday
Savara (NASDAQ:SVRA) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at...
MarketBeat
Savara (NASDAQ:SVRA) Coverage Initiated by Analysts at Oppenheimer
Oppenheimer started coverage on Savara in a report on Friday. They issued an "outperform" rating and a $11.00 price target for the company...
MarketBeat
FY2026 EPS Estimates for Savara Decreased by Lifesci Capital
Savara Inc. (NASDAQ:SVRA - Free Report) - Lifesci Capital cut their FY2026 EPS estimates for shares of Savara in a research report issued on Thursday, April 16th. Lifesci Capital analyst F. Brisebois...
MarketBeat
Savara (NASDAQ:SVRA) Stock Price Up 2.5% - Here's Why
Savara (NASDAQ:SVRA) Trading Up 2.5% - Here's What Happened...
MarketBeat
<
1
2
...
>
Advertisement|Remove ads.
Latest SVRA News
ViewSavara Announces Participation in the 2026 Jefferies Global Healthcare Conference
Business Wire
Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026
Business Wire
Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Business Wire
Advertisement|Remove ads.